Briefing
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
A phase 3 trial used serial ctDNA testing for up to a year after cystectomy for muscle-invasive bladder cancer to select who received adjuvant atezolizumab. The abstract does not name the assay.
- Design: Evidence level 1
- Assay: Not named in the abstract
The New England Journal of MedicinePubMed 41124204DOI 10.1056/NEJMoa2511885